Pulmotect Provides Results from Two Randomized, Placebo Cont

-Positive Efficacy Signals from Trials of Prevention and Treatment of COVID-19--Improvement of Respiratory Symptoms and Fewer Intensive Care Admissions from Previously Reported Trial in Patients with COVID-19--Potential Activity Against All SARS-CoV-2 Variants-HOUSTON--(BUSINESS WIRE)--#biotech--Pulmotect, Inc., a c...

Related Keywords

New Jersey , United States , Houston , Texas , , Us Department Of Defense , Pulmotect Inc , National Institutes Of Health , World Health Organization , Program Executive Office For Chemical , Us Army Contracting , Nuclear Defense , Defense Consortium , Research Institute Of Texas , Positive Efficacy Signals , Respiratory Symptoms , Fewer Intensive Care Admissions , Previously Reported Trial , Potential Activity Against All , Colin Broom , Dose Study , Infection Rate , Adults Exposed , Ordinal Scale , Clinical Improvement , Adults Positive , Program Executive Office , Contracting Command , National Institutes , Cancer Prevention , Research Institute , Fannin Innovation , Fannin Innovation Studio ,